AbbVie (ABBV) FCF Payout Ratio Growth (3y) (2016 - 2026)
AbbVie (ABBV) FCF Payout Ratio Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -24.09% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 32.12% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -11.39% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -43.51% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -251.57% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 9.57% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -11.54% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 111.34% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.12% |
| Mar 31, 2026 | 9.35% |
| Dec 31, 2025 | 19.68% |
| Sep 30, 2025 | 9.12% |
| Jun 30, 2025 | 4.94% |
| Mar 31, 2025 | 57.75% |
| Dec 31, 2024 | -4.89% |
| Sep 30, 2024 | 20.84% |
| Jun 30, 2024 | 40.16% |
| Mar 31, 2024 | 13.32% |
| Dec 31, 2023 | 7.93% |
| Sep 30, 2023 | -1.53% |
| Jun 30, 2023 | -10.77% |
| Mar 31, 2023 | 11.50% |
| Dec 31, 2022 | -12.16% |
| Sep 30, 2022 | -2.29% |
| Jun 30, 2022 | -8.71% |
| Mar 31, 2022 | -0.83% |
| Dec 31, 2021 | 2.17% |
| Sep 30, 2021 | -4.50% |